The advancements in medicine had been rather unstable lately—progress was happening, yes, but the momentum was erratic, like a flame that flickers with every gust. With the rapid development of treatments across a wide spectrum of diseases, the world found itself in the midst of a new medical era. Integration efforts for these medicines were underway, and global trial runs had begun in preparation for mass production and international distribution. The ambition was big. The effort—massive.
In Leonamon, the breakthroughs were soaring sky-high. The contributions were unmatched, particularly when it came to basic, yet vital necessities—things like antibiotics, immune boosters, and other essential treatments were already rolling off production lines.
Still, not all the medicines were finished. Some were halfway there—tangled in refinement phases, awaiting perfection.
And yet, oddly enough, the most heavily produced and widely sold item wasn't something lifesaving or disease-curing.
